



Press release
July 2, 2015
Gothenburg

Share warrant program fully subscribed

XVIVO Perfusion AB's share warrant program 2015/2017 is fully subscribed. A total of 215,000 warrants with the right to subscribe for new shares were issued. Each warrant has in June 2017 the right to subscribe for one new share at a price of SEK 60.92.

The annual shareholder meeting April 23, 2015 approved the warrant program of a maximum of 215,000 warrants to be offered to all employees in XVIVO Perfusion AB. Upon full exercise of the warrants, the share capital increase is SEK 5,500 corresponding to a dilution of about 1 percent of the total number of shares and votes.

Magnus Nilsson, CEO of XVIVO Perfusion: "The broad support is very encouraging and it gives all of our employees a stronger shareholder interest and an even stronger incentive to fulfill our goals."

July 2, 2015
Gothenburg
XVIVO Perfusion AB (publ)

For further information, please contact

Christoffer Rosenblad, CFO, +46 031-788 21 59, christoffer.rosenblad@xvivoperfusion.com

XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation. The company is headquartered in Gothenburg, Sweden, and has one office in the USA. The Xvivo share is listed on NASDAQ OMX First North and has the ticker symbol XVIVO. More information can be found on the website www.xvivoperfusion.com. The Certified Adviser is Redeye, www.redeye.se.

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity number 556561-0424.
Tel: +46 31 788 21 50. Fax: +46 31 788 21 69.
E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com
The information was submitted for publication on July 2, 2015 at 8:30 a.m.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.